COMPASS Pathways Awarded Patent for Psilocybin Formulation COMP360

The scope and validity of the patent will depend on how x-ray diffraction data is interpreted.

December 31, 2019

COMPASS Pathways was granted U.S. Patent No. 10,519,175 which covers COMP360, their investigational psilocybin formulation which developed and produced by COMPASS Pathways. The patent covers methods of treating drug-resistant depression by administering particular dosage forms. Those dosage forms include explicit requirements that are based on interpreting x-ray diffraction data.